Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging
Conditions
Endometrial Cancer - Cervical Cancer
Conditions: official terms
Uterine Cervical Neoplasms
Study Type
Interventional
Study Phase
N/A
Study Design
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Intervention
Name: IC Green
Type: Drug
Overall Status
Recruiting
Summary
Description:

This is a multi-institutional study investigating the sensitivity and negative predictive value of sentinel lymph nodes mapped with robotic assisted near infrared imaging after cervical injection of indocyanine green (ICG) dye for women with stage I endometrial or cervical cancer at the time of their robotic surgical staging.

Patients will receive cervical injection of 1mg ICG after induction of anesthesia followed by sentinel lymph node mapping using robotic assisted fluorescence imaging. The sentinel lymph nodes identified will be removed and sent for ultraprocessing by pathology. The non-sentinel pelvic and para-aortic (if indicated) non-sentinel nodes will be removed and sent for routine pathologic processing according to standard of care for these surgical procedures. The pathologic results of the sentinel and non-sentinel nodes will be evaluated for sensitivity and negative predictive value in their ability to detect metastatic disease.
Detailed Description
Brief Summary:

Patients with early stage endometrial and cervical cancer who are undergoing robotic surgery to remove the uterus, cervix and lymph nodes will have dye injected into the cervix after they are asleep from anesthesia prior to performing the surgery. During the surgery, the surgeon will activate the robotic camera that is being used to visualize the internal organs changing it to a special mode of imaging called near infrared imaging. The near infrared imaging will allow the surgeon to see where the dye that was injected into the cervix has spread. The dye travels through vessels called lymphatic channels to nodules called "sentinel lymph nodes". These are the tissues the surgeon is most interested in removing in order to see if there has been spread of their cancer to those nodules. The dye that travels to the lymph nodes makes them more easily visible to the surgeon. Without the dye, these nodes are indistinguishable from the surrounding fatty tissue.

The nodes that have dye in them will be removed from the patient and sent to the pathologist, where they will be very closely examined, called ultrasectioning, for cancer spread. The surgeon will remove the remaining lymphatic tissue (all of the fatty and lymphatic tissue that surrounded the sentinel lymph node that did not stain with the dye), as these are the "non-sentinel lymph nodes", and are the tissue that is traditionally removed with endometrial and cervical cancer surgery as part of standard of care. These non-sentinel lymph nodes will also be examined for evidence of cancer spread. The researchers will compare the pathology results from the sentinel nodes and non-sentinel nodes. The researchers hypothesize that the sentinel nodes contain cancer cells at least 90% of the time when there is cancer found in the non-sentinel nodes.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Patients must be women 18 years and older who have biopsy proven endometrial or cervical carcinoma (of any histologic subtype).

- Surgical staging with the da Vinci Si robotic tool must be planned with a planned pelvic and, in the case of endometrial cancer, a para-aortic lymphadenectomy

- Patients must meet criteria for robotic surgical approach:

- Patients must have either a clinical stage I endometrial (of any histologic grade) or FIGO stage IA2 or IB1 (<4cm) cervical squamous, adenocarcinoma or adenosquamous carcinoma.

- Patients must be able to sign an informed consent in English language.

- Patients with known liver disease will require normal range liver function tests as determined by pre-operative labs drawn within 30 days of surgery.

Exclusion Criteria:

- Patients who have iodide allergies

- Patients who have had previous retroperitoneal surgery

- Patients on whom pelvic+/- para-aortic lymphadenectomy is not planned as part of their surgical staging.

- Patients who have received previous treatment for their endometrial or cervical cancer (particularly hysterectomy or pelvic radiation).

- Patients who are pregnant.

- Patients with documented liver disease who have abnormalities of liver function tests.
Locations
USA Mitchell Cancer Institute
Mobile, Alabama, United States
Status: Recruiting
Contact: Jennifer Scalici, MD - 251-445-9866
Indiana University
Indianapolis, Indiana, United States
Status: Recruiting
Contact: Emma Rossi, MD - 317-944-7026
St. Elizabeth Healthcare
Edgewood, Kentucky, United States
Status: Recruiting
Contact: Kevin Schuler, MD - 859-301-5473 - darla.hehman@stelizabeth.com
Sunrise Hospital and Medical Center
Las Vegas, Nevada, United States
Status: Recruiting
Contact: Lynn Kowalski, MD - 702-739-6467
University of North Carolina
Chapel Hill, North Carolina, United States
Status: Recruiting
Contact: Amanda Jackson, MD - 919-843-2077 - jbh@med.unc.edu
Tri Health Good Smaritan Hospital
Cincinnati, Ohio, United States
Status: Recruiting
Contact: Kevin Schuler, MD - 513-862-1892 - Diann_fischesser@trihealth.com
University of Virginia Medical Center
Charlottesville, Virginia, United States
Status: Recruiting
Contact: Leigh Cantrell, MD - 434-243-0032
Start Date
May 2012
Completion Date
May 2017
Sponsors
Indiana University
Source
Indiana University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page